BCAB vs LEN · $5.9M cap vs rev $34.19B
Bioatla Inc (BCAB) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Bioatla Inc (BCAB) is a biotechnology company listed on NASDAQ.
LEN (LEN) common stock.
Latest reported BCAB revenue for 2023-09-30 was $0. Net income was -$33.3M. BCAB currently screens at market cap $5.9M.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
BCAB currently screens at market cap $5.9M. LEN currently screens at market cap $0.
Not investment advice. Open the BCAB and LEN stock pages for the full models.
Not investment advice.